Ritlecitinib

Phase 3

PFIZER (PFE)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

PFEPhase 3$160.0B

Ritlecitinib Phase 3 Est. Readout

Ritlecitinib• Stable Nonsegmental Vitiligo1,571

Q3 2027~QConfirmedSTALE

CT.gov

00%

Q2 '27

PFEPhase 3$160.0B

Ritlecitinib Phase 3 Est. Readout

Ritlecitinib• Stable Nonsegmental Vitiligo400

Q2 2027~QConfirmedSTALE

CT.gov

00%

Q1 '27

PFEPhase 2$160.0B

Ritlecitinib Phase 2 Est. Readout

Ritlecitinib• Stable Nonsegmental Vitiligo240

Q1 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Stable Nonsegmental Vitiligo

View Full Landscape

Drug Information

Target Indication

Stable Nonsegmental Vitiligo

Clinical Trial

NCT05583526

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/15/2023

Litfulo

Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts